3 trial readouts that could shake up the obesity market this year

Analysts expect the space to reach a value of potentially hundreds of billions of dollars over the coming years. And with so much upside, new entrants are racing into the clinic to get a piece of the action. Small biotechs and Big Pharma alike are betting on both improved GLP-1s and novel approaches.

While only two companies currently have blockbuster obesity meds approved in the GLP-1 arena, more could be way soon. Here are some upcoming obesity trial readouts to watch in 2025.